KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum
March 27 2017 - 07:30AM
KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs, announced today that Andrew Barrett, Ph.D.,
Senior Director, Scientific Affairs, will present at the Sachs
Associates 2nd Annual Neuroscience Biopartnering and Investment
Forum being held March 27, 2017, at the New York Academy of
Sciences.
Details of KemPharm's presentation are as follows:
|
|
|
Event: |
|
2nd
Annual Neuroscience Biopartnering and Investment
Forum |
Date: |
|
Monday,
March 27, 2017 |
Time: |
|
3:20 p.m.
ET |
Location: |
|
New York
Academy of Sciences7 World Trade Center250 Greenwich St., 40th
Floor (D Elevator Bank)New York, NY 10007 |
|
|
|
About KemPharm
KemPharm is a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs to treat serious medical conditions through
its Ligand Activated Therapy (LAT) platform technology.
KemPharm utilizes its LAT platform technology to generate improved
prodrug versions of FDA-approved drugs in the high need areas of
pain, attention deficit hyperactivity disorder (ADHD) and other
central nervous system disorders. KemPharm’s co-lead clinical
development candidates are KP415, an extended-release prodrug of
methylphenidate for the treatment of ADHD, and KP201/IR, an
acetaminophen-free formulation of the company’s immediate release
abuse deterrent hydrocodone product candidate, KP201. For
more information on KemPharm and its pipeline of prodrug product
candidates visit www.kempharm.com.
Investor Contacts:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
jrando@tiberend.com
jdrumm@tiberend.com
Media Contact:
Daniel L. Cohen
Executive VP, Government and Public Relations
KemPharm, Inc.
202-329-1825
dcohen@kempharm.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Feb 2024 to Mar 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Mar 2023 to Mar 2024